A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
The Population Council presented new research on male contraception, including a hormonal implant that inhibits sperm production and a study on a combined transdermal gel. The council also discussed 'green contraception,' which refers to methods that minimize environmental impact.
Exome sequencing may miss a high proportion of clinically relevant regions in key disease-causing genes, raising concerns about patient diagnosis. The study's findings highlight the need for improved methods to provide reliable coverage of these genes.
Research identifies new ways to ease cancer therapy effects and enhance patient well-being, from fertility preservation techniques to earlier palliative care. Studies show improved survival rates and reduced side effects for certain treatments.
A combination therapy of vermurafenib, cetuximab and irinotecan has shown significant improvements in patients with advanced colorectal cancer, achieving a 50% response rate in an early Phase I trial. The treatment targets BRAF-mutated patients who have previously shown poor response rates to single-agent therapies.
A clinical trial has shown that a combination of drugs, including olaparib and cediranib, can significantly improve progression-free survival for patients with recurrent ovarian cancer. The study found that the combination therapy doubled the benefit of using olaparib alone.
Researchers report promising results from a phase I study on MPDL3280A, an investigational drug for treating advanced bladder cancer. The trial showed improved response rates among patients with PD-L1-positive tumors, with 7% achieving complete responses.
Research reveals that hospital mortality rates are highest following surgery during afternoon hours, on weekends, and in February. A study of 218,758 patients found a significant increase in risk of death during these times.
Researchers presented promising results from four clinical trials featuring new targeted drugs for advanced ovarian, lung and thyroid cancers, as well as chronic lymphocytic leukemia. These treatments showed potential to slow disease progression and improve survival rates for patients with relapses or treatment resistance.
A University of Colorado Cancer Center study found NTRK1 mutations in over 1% of non-small cell lung cancer patients. The study also developed a test for rapid detection of NTRK1 oncogenes, marking a new frontier in lung cancer treatment.
A non-invasive breath test has been developed to detect lung cancer by analyzing volatile organic compounds in exhaled breath. The device can distinguish between patients with lung cancer and chronic obstructive pulmonary disease (COPD), as well as define the stage of any present cancer.
The European Society of Anaesthesiology and Intensive Care invites speakers to challenge common assumptions about end-of-life care. Raanan Gillon presents a case for weighing individual patient circumstances over age when deciding on life-prolonging therapies.
OMP-54F28, a Wnt inhibitor targeting cancer stem cells, has shown promising results in a Phase I clinical trial. The drug was generally well-tolerated and resulted in stable disease for over six months in several patients with advanced solid tumors.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
A study of 55 million people worldwide adds evidence that weekend hospital admissions have a higher mortality rate compared to weekdays. The analysis found patients admitted on weekends had an increased risk of death, with subgroup analysis revealing this trend in nearly all categories.
A phase I and II clinical trial demonstrated a near doubling of progression-free survival benefit for the combination therapy compared to olaparib alone. The study results showed significant improvement with the use of the combination drug therapy for recurrent ovarian cancer, suggesting a new treatment option for patients.